Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.38 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.38 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.38 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.38 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.38 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.38 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.38 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.38 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27598470 | 0.98 | CYP1A2 (0.43) | CYP1A2FOLH1TET2KDM4AKDM4C | |
| Hydrochloric Acid SCHEMBL1267577 | 0.84 | ALDH1A1 (0.38) | CYP1A2FOLH1TET2KDM4AKDM4C | |
| SCHEMBL27598461 | 0.82 | ALDH1A1 (0.39) | CYP1A2FOLH1TET2KDM4AKDM4C | |
| SCHEMBL8080753 | 0.81 | CYP1A2 (0.50) | CYP1A2FOLH1TET2KDM4AKDM4C | |
| SCHEMBL27598585 | 0.79 | CYP1A2 (0.38) | CYP1A2FOLH1TET2KDM4AKDM4C | |
| SCHEMBL25381839 | 0.78 | GABRR1 (0.43) | GSR | |
| SCHEMBL25381838 | 0.78 | GABRR1 (0.43) | GSR | |
| SCHEMBL9183627 | 0.78 | TDP1 (0.37) | FOLH1ALDH1A1 | |
| SCHEMBL9184977 | 0.78 | TDP1 (0.37) | FOLH1ALDH1A1 | |
| SCHEMBL9183621 | 0.78 | TDP1 (0.37) | FOLH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026383-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives | BASF SE (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | CIBA SPECIALTY CHEMICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-7855302-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino-3.5-dihydroxyhepanoic acid derivatives and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7692034-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-04-06 | — | — | US | disclosed |
| EP-2161250-A1 | Process for the preparatiom of 7-amino-syn-3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-03-10 | — | — | EP | disclosed |
| EP-1404642-B1 | Process for the preparatiom of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-7504532-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-17 | — | — | US | disclosed |
| US-20080312466-A1 | Synthesis and intermediates | OHRLEIN REINHOLD | 2008-12-18 | — | — | US | disclosed |
| US-7420078-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | BASF SE (DE) | 2008-05-29 | — | — | US | disclosed |
| US-7317123-B2 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2008-01-08 | — | — | US | disclosed |
| US-20070142662-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2007-06-21 | — | — | US | disclosed |
| US-7199261-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2007-04-03 | — | — | US | disclosed |
| US-20050033086-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | BASF SE (DE) | 2005-02-10 | — | — | US | disclosed |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20040186313-A1 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3 5-dihydroxy heptanoic acid derivatives, and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. | 2004-09-23 | — | — | US | disclosed |
| EP-1404642-A2 | SYNTHESIS AND INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004455-A2 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | HMGCR, SREBF1, LCAT | GABRP 4635/4885GABRD 4377/4885GABRA1 3341/4885 |
| US-20040186313-A1 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3 5-dihydroxy heptanoic acid derivatives, and intermediates thereof | HMGCR, CYP46A1, CYP7A1 | GABRP 4166/4885GABRD 1475/4885GABRA1 1461/4885 |
| US-20080312466-A1 | Synthesis and intermediates | HMGCR, SREBF1, COASY | GABRP 4589/4885GABRD 4295/4885GABRA1 3050/4885 |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | HMGCR, DHCR7, CYP8B1 | GABRP 2927/4885GABRD 700/4885GABRA1 1763/4885 |
| US-20070142662-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | HMGCR, DHCR7, HCAR3 | GABRP 2486/4885GABRD 492/4885GABRA1 1423/4885 |
| US-20050033086-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | HMGCR, DHCR7, HCAR3 | GABRP 2486/4885GABRD 492/4885GABRA1 1423/4885 |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | HMGCR, DHCR7, CYP8B1 | GABRP 2137/4885GABRD 556/4885GABRA1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.